Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) traded up 4.8% on Friday . The company traded as high as $23.20 and last traded at $23.01, with a volume of 90,468 shares. The stock had previously closed at $21.95.

A number of analysts recently weighed in on the stock. TheStreet raised shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research report on Friday, July 29th. Canaccord Genuity assumed coverage on shares of Blueprint Medicines Corp. in a research report on Friday. They set a “buy” rating and a $26.00 price target for the company. Raymond James Financial Inc. assumed coverage on shares of Blueprint Medicines Corp. in a research report on Friday, May 27th. They set an “outperform” rating and a $23.00 price target for the company. Cowen and Company reaffirmed a “buy” rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, May 10th. Finally, Zacks Investment Research cut shares of Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $28.14.

The company has a 50-day moving average price of $20.46 and a 200 day moving average price of $18.20. The stock’s market cap is $624.51 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last released its earnings results on Tuesday, May 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.13. The company earned $6.90 million during the quarter, compared to analysts’ expectations of $3.24 million. The company’s revenue for the quarter was up 961.5% on a year-over-year basis. Equities research analysts expect that Blueprint Medicines Corp. will post ($2.98) earnings per share for the current fiscal year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $20.03, for a total value of $340,510.00. Following the completion of the sale, the chief executive officer now owns 92,486 shares in the company, valued at approximately $1,852,494.58. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

An institutional investor recently raised its position in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC increased its position in Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned approximately 2.73% of Blueprint Medicines Corp. worth $19,500,000 at the end of the most recent quarter.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.